Last Updated: June 25, 2026

Details for Patent: 9,180,040


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,180,040 protect, and when does it expire?

Patent 9,180,040 protects MIUDELLA and is included in one NDA.

This patent has nine patent family members in seven countries.

Summary for Patent: 9,180,040
Title:Intrauterine device with retrieval thread
Abstract:An intrauterine contraceptive system may include a contraceptive intrauterine device, a retrieval thread permanently attached to the intrauterine device and an insertion device for inserting the intrauterine device into a uterus. The system may also include a release thread releasably coupled with the intrauterine device. The intrauterine device may be deployable out of a distal end of the insertion device and may be configured to change from a delivery configuration when housed in the insertion device to a deployed configuration when deployed in a uterus. The retrieval thread and the optional release thread may be at least partially housed within the insertion device during insertion of the intrauterine device into the uterus. The release thread may extend from the intrauterine device through the insertion device to an attachment point at or near a proximal end of the insertion device.
Inventor(s):Michael Tal, Bob H. Katz, Mark James DeBisschop
Assignee: Sebela Vlc Ltd
Application Number:US14/057,297
Patent Claim Types:
see list of patent claims
Delivery; Device;
Patent landscape, scope, and claims:

Scope and claims of US Patent 9,180,040 (intrauterine contraceptive system with permanent retrieval thread and removable release thread)

US 9,180,040 claims a specific intrauterine contraceptive system architecture combining (1) a permanently attached retrieval thread on the IUD frame/device with a defined length range, (2) a second “release thread” that is temporarily releasably coupled to the IUD for attachment to an inserter and is then pulled off after securing, and (3) a particular routing path where the release thread travels from a proximal end of the inserter through the shaft and through the IUD to an attachment point near the proximal end. Claim 1 also requires the retrieval thread length to be 5 to 9 cm and expressly ties the inserter deployment mechanics to configuration change from housed-to-deployed in the uterus. Dependent claims add insertion-time containment of the retrieval thread, an opening on the IUD/frame that receives the retrieval attachment and allows passage of the release thread, and a contrast-color pattern on the retrieval thread with defined segment geometry (including a segment between 2 and 3 cm from the attachment point). Claims 7 to 12 track an IUD/device-alone subset of the same architecture.


What patents protect intrauterine contraceptive systems with a permanent retrieval thread and a removable release thread?

US 9,180,040 is directed to an intrauterine contraceptive system and device construction that separates patient-facing retrieval from inserter coupling mechanics. The protected elements are not just “threads” generally, but the two-thread functional split (permanent retrieval vs releasable release) plus their routing through the inserter and IUD, plus visible retrieval-color encoding.

Core claim elements in plain claim language

Claim 1 requires:

  1. An intrauterine contraceptive system comprising:
    • A “contraceptive intrauterine device” (IUD).
    • A retrieval thread permanently attached to the IUD, with length 5 to 9 cm.
    • An insertion device for inserting the IUD, with shaft, proximal end, distal end.
    • A release thread releasably coupled to the IUD and not permanently attached, so it can be pulled off once it is no longer needed to secure the IUD to the insertion device.
  2. Release thread routing path when coupled with the insertion device:
    • Extends from a first end at the proximal end of the insertion device,
    • Through the shaft,
    • Through the intrauterine device,
    • To an attachment point at or near the proximal end of the insertion device.
  3. Deployment configuration change:
    • The IUD is deployable out of the distal end of the insertion device,
    • Changes from delivery configuration (housed in inserter) to deployed configuration (in uterus).

Dependent claim 2 requires:

  • Retrieval thread is at least partially housed within the insertion device during insertion.

Dependent claim 3 adds an IUD opening:

  • IUD includes an opening.
  • Retrieval thread attached near opening.
  • Release thread passes through opening.

Dependent claims 4-6 add a color pattern for retrieval visibility:

  • Retrieval thread has:
    • first portion with first color
    • second portion with second color
    • colors contrast sufficiently to be visible during physical exam.
  • Claim 5 adds distance geometry:
    • first portion extends from attachment point to a location 2 to 3 cm from attachment point.
  • Claim 6 adds a third portion:
    • third portion has first color
    • second portion comprises a band of second color
    • first and third portions are on either side of the band.

Claims 7-12 repeat the same architecture at the IUD/device level (frame + threads), with the device including an opening option and color pattern options. Claim 7 includes the releasable release-thread coupling concept tied to coupling with an insertion device, but it is framed as an “intrauterine contraceptive device” claim.


How broad are the claims of US 9,180,040: what exactly do they cover?

The claim scope hinges on a few structural and functional limitations that, taken together, narrow the likely design-around space more than a “thread-based” title suggests.

1) Two-thread architecture is mandatory

The claims require:

  • A retrieval thread that is permanently attached to the IUD/frame (for long-term patient use and exam visibility).
  • A second thread, the release thread, that is releasably coupled and not permanently attached to the IUD/frame (so it can be pulled off once the IUD is secured to the inserter).

A design that uses a single permanent thread, or that uses a permanently attached inserter-coupling element, would fall outside the claim by failing the “not permanently attached / releasably coupled” separation.

2) Retrieval-thread length is a hard numeric gate

Retrieval thread length “between 5 cm and 9 cm” (claims 1 and 7) is a specific range limitation. It constrains both literal infringement and evaluation of “equivalents” because numeric range limitations are frequently treated as materially limiting in claim construction.

3) Release-thread routing through the inserter and through the IUD is required

Claim 1 specifies:

  • proximal end of insertion device → through shaft → through IUD → attachment point near proximal end.

This is not satisfied by a release thread that only couples at one interface without passing through the IUD opening/structure. Claim 3 further specifies passing through an IUD opening.

4) Deployment mechanics are part of the claim

Claim 1’s IUD must be deployable out of the distal end of the inserter and configured to change from a delivery configuration to a deployed configuration. This is likely inherent for most inserter-based IUD systems, but it locks the claim to a delivery system with an inserter-driven transition rather than, for example, a system inserted using a different mechanism.

5) Color pattern claims are narrower but commercially relevant

Claims 4-6 and 10-12 add:

  • contrasting first and second colors for visibility during physical examination,
  • with a defined geometry (first portion length from attachment point 2-3 cm),
  • and a third portion forming a banded second color region with first color segments on either side.

These limitations are narrower than the core thread architecture but are meaningful for product differentiation and retrieval assurance.


What is the patentable subject matter in claims 1 and 7 compared with dependent claims?

A clean way to separate scope:

Independent coverage (claims 1 and 7)

  • Permanent retrieval thread of defined length (5-9 cm).
  • Removably coupled release thread used for inserter coupling, pulled off after securing.
  • Inserter geometry and release-thread routing through shaft and through IUD to proximal attachment point.
  • Delivery-to-deployed configuration change.

Dependent narrowing (claims 2-6, 8-12)

  • Retrieval thread housed within inserter during insertion (claim 2 / 9).
  • IUD opening for routing and attachment (claim 3 / 8).
  • Retrieval thread color contrast (claims 4 / 10).
  • Color segment placement/dimensions: 2-3 cm segment distance (claim 5 / 11).
  • Color banding and third portion placement (claim 6 / 12).

Which design-arounds could avoid literal infringement of US 9,180,040?

The claims are structured so that multiple different elements must be avoided simultaneously to exit literal infringement, though each element offers an “escape hatch.”

A) Change retrieval thread length outside 5–9 cm

A retrieval thread shorter than 5 cm or longer than 9 cm removes one key numeric limitation. If everything else remains the same, the claim is still not met literally.

B) Remove the second thread concept

If the inserter uses a different mechanism than a releasably coupled release thread that is pulled off after securing, then the system likely fails the “release thread not permanently attached / pulled off” requirement.

C) Alter the release thread routing path

If a release thread does not extend from the inserter proximal end through shaft through the IUD to a proximal attachment point near the proximal end, the claim 1 routing is not satisfied.

D) Eliminate the IUD opening limitation

If the IUD does not include an opening and the routing is achieved via other structural features, dependent claim 3/8 is avoided. But independent claim 1/7 does not expressly require an opening; it only requires that the release thread passes through the intrauterine device.

E) Remove the contrast color pattern (or change geometry)

Color claims 4-6 and 10-12 provide additional, narrower protection. If a retrieval thread has no contrasting first/second colors visible in physical exam, or the segment distances/banding do not match, those dependent claims are not met.


How strong is the patent estate around US 9,180,040 for enforcing IUD delivery thread architectures?

Without a full file history, citation list, and the rest of the family (continuations/divisionals) the broader estate cannot be mapped from the single patent number alone. Under the constraint to not speculate, the only enforceable “strength” assessment that can be made from the claim set you provided is structural:

  • The independent claims are tight: they combine a specific dual-thread architecture, numeric retrieval length, and a specific release thread routing path tied to insertion-device proximal attachment.
  • The dependent claims target commercial differentiators (visible contrasting colors and segmented pattern), which can broaden enforceability against competing products even if they change some mechanical dimensions, as long as the independent limitations are still met.

What generic entry risks exist for designs that attempt to replicate IUD hardware?

IUDs are typically “device-like” products rather than classic small-molecule generics. “Generic entry risks” translate into infringement risk for competing manufacturers attempting to market comparable intrauterine contraceptive devices and inserter systems.

Likely high-risk replication features

  • Dual-thread architecture with permanent retrieval thread and removable release thread.
  • Release-thread routing through the inserter shaft and through the IUD.
  • Retrieval thread length in the 5–9 cm range.
  • Color contrast segmented as claimed if competing designs aim for exam visibility.

Lower-risk features

  • Single-thread designs that do not use a removable release thread.
  • Systems that embed retrieval in a way that changes the length beyond 5–9 cm.
  • Retrieval colorways that omit the claimed geometry (2–3 cm segment placement and banded second-color region).

What does the claim set suggest about manufacturing and testing barriers?

The claims focus on:

  • placement of attachment points (near proximal end for release thread),
  • routing alignment so the release thread passes through the intrauterine device,
  • integration of an opening (dependent claims 3/8),
  • and consistency of retrieval thread length and segment color geometry.

From a product-development and validation standpoint, these are process-controlled features rather than broad functional outcomes. That tends to create measurable acceptance criteria in QA and may reduce easy “equivalent” substitutions.


Claim chart style mapping: key limitations by claim number

Limitation Claim 1 Claim 2 Claim 3 Claim 4 Claim 5 Claim 6 Claim 7 Claim 8 Claim 9 Claim 10 Claim 11 Claim 12
Intrauterine contraceptive system/device Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Contraceptive intrauterine device/frame Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Retrieval thread permanently attached Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Retrieval thread length 5–9 cm Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Insertion device has shaft, proximal, distal Yes Yes Yes Yes Yes Yes (via coupling concept) (via coupling concept) (via coupling concept) (via coupling concept) (via coupling concept) (via coupling concept)
Release thread releasably coupled, not permanently attached Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Release thread pulled off after securing Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Release thread routing: proximal end through shaft through IUD to attachment point near proximal end Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
IUD deployable from distal end, delivery-to-deployed config Yes Yes Yes Yes Yes Yes (implied in system claim 1; not stated as explicitly in 7) (via coupling concept) (via insertion device coupling concept) (via coupling concept) (via coupling concept) (via coupling concept)
Retrieval thread at least partially housed in insertion device during insertion No Yes Yes Yes Yes Yes No No Yes Yes Yes Yes
IUD/frame has opening; retrieval attached near opening; release passes through opening No No Yes Yes Yes Yes No Yes No Yes Yes Yes
Retrieval thread has first/second contrasting colors No No No Yes Yes Yes No No No Yes Yes Yes
First color portion extends 2–3 cm from attachment point No No No No Yes Yes No No No No Yes Yes
Third portion: first color on both sides of a band of second color No No No No No Yes No No No No No Yes

What patents protect IUD color-visibility retrieval features similar to claims 4-6?

Your provided claim set ties visibility to:

  • contrasting colors on the retrieval thread,
  • a defined segment geometry (2–3 cm from attachment point, and banding with first color portions on either side).

This is a narrow and patentable-looking feature set. However, the rest of the patent landscape for such color visibility features cannot be enumerated from the single patent number without underlying bibliographic data, citations, and family members.


Orange Book status, FDA regulatory status, and exclusivity timelines for US 9,180,040

US patents that are device component patents generally do not map to the Orange Book. The claim set you supplied does not identify:

  • an FDA-listed drug product,
  • a use code,
  • an Orange Book listing number,
  • or an FDA pathway. No regulatory status, exclusivity, or FDA milestone data can be derived from the claims alone.

Key Takeaways

  • US 9,180,040 protects a dual-thread IUD delivery concept: a permanent patient retrieval thread (5–9 cm) plus a temporary release thread that is releasably coupled and pulled off after securing the IUD to an inserter.
  • The independent claims require a specific release-thread routing from the inserter proximal end through the inserter shaft and through the intrauterine device to a proximal attachment point.
  • Dependent claims add mechanical insertion-time containment (retrieval thread housed in inserter), optional routing through an IUD opening, and segmented contrasting color patterns for retrieval visibility.
  • Design-around leverage points are numeric (retrieval length), structural (two-thread architecture and releasable coupling), and routing-path specific (through the IUD and to a proximal attachment point), with additional escape options around color segment geometry.

FAQs

  1. If a competitor uses a permanently attached coupling thread for insertion instead of a releasable release thread, does it avoid claim 1?
  2. What happens if the retrieval thread length is 4.8 cm or 9.2 cm while the rest of the system matches claim 1?
  3. Do claims 4-6 apply if the retrieval thread is visible but uses only one uniform color?
  4. Does adding an IUD opening only for the release-thread passage, without changing retrieval attachment geometry, satisfy dependent claim 3?
  5. Can a product infringe claim 7 (device-level claim) without using the same inserter architecture described in claim 1?

References

  1. US Patent 9,180,040, “Intrauterine contraceptive system and device,” claims 1-12 (as provided).

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,180,040

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sebela Womens Hlth MIUDELLA copper SYSTEM;INTRAUTERINE 218201-001 Feb 24, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.